Effects of Various Interventions on Non-alcoholic Fatty Liver Disease (NAFLD): A Systematic Review and Network Meta-analysis

Overview

Journal Front Pharmacol

Date 2023 Apr 17

PMID 37063273

Authors

Xinchen Wang

Xiaoqian Jin

Hancheng Li

Xianyu Zhang

Xi Chen

Kuan Lu

Chenliang Chu

Affiliations

Soon will be listed here.

Abstract

With the increasing prevalence of obesity and metabolic syndrome, the incidence of non-alcoholic fatty liver disease (NAFLD) is also increasing. In the next decade, NAFLD may become the main cause of liver transplantation. Therefore, the choice of treatment plan is particularly important. The purpose of this study was to compare several interventions in the treatment of NAFLD to provide some reference for clinicians in selecting treatment methods. We searched Public Medicine (PubMed), Medline, Excerpta Medica Database (Embase), and Cochrane Library from January 2013 to January 2023 to identify randomized controlled trials (RCTs) published in English. The network meta-analysis was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Forty-three studies accounting for a total of 2,969 patients were included, and alanine aminotransferase (ALT), total cholesterol (TC), and low-density lipoprotein cholesterol (LDL) were selected as outcome measures for analysis and comparison. We evaluated the results of drug, diet, and lifestyle interventions between the intervention and control groups. Curcumin (CUN) and probiotics (PTC) were selected for medication, the Mediterranean diet (MDED) was selected for special diet (SPD), and various kinds of exercise and lifestyle advice were selected for lifestyle interventions (LFT). The SUCRA was used to rank interventions according to the effect on ALT indicators (SUCRA: PTC 80.3%, SPD 65.2%, LFT 61.4%, PLB 32.8%, CUN 10.2%), TC indicators (SUCRA: PTC 89.4%, SPD 64%, CUN 34%, LFT 36.6%, PLB 17%), and LDL indicators (SUCRA: PTC 84.2%, CUN 69.5%, LFT 51.7%, PLB 30.1%, SPD 14.5%). The pairwise meta-analysis results showed that MDED was significantly better than NT in improving ALT [SMD 1.99, 95% CI (0.38, 3.60)]. In terms of improving TC and LDL, ATS was significantly better than NT [SMD 0.19, 95% CI (0.03, 0.36)] [SMD 0.18, 95% CI (0.01, 0.35)]. Our study showed that PTC is most likely to be the most effective treatment for improving NAFLD indicators. Professional advice on diet or exercise was more effective in treating NAFLD than no intervention.

Citing Articles

Evaluating Bioactive-Substance-Based Interventions for Adults with MASLD: Results from a Systematic Scoping Review.

Handu D, Stote K, Piemonte T Nutrients. 2025; 17(3).

PMID: 39940310 PMC: 11820841. DOI: 10.3390/nu17030453.

NAFLD in the 21st Century: Current Knowledge Regarding Its Pathogenesis, Diagnosis and Therapeutics.

Kounatidis D, Vallianou N, Geladari E, Panoilia M, Daskou A, Stratigou T Biomedicines. 2024; 12(4).

PMID: 38672181 PMC: 11048710. DOI: 10.3390/biomedicines12040826.

Mechanisms of ferroptosis in nonalcoholic fatty liver disease and therapeutic effects of traditional Chinese medicine: a review.

Wang N, Que H, Luo Q, Zheng W, Li H, Wang Q Front Med (Lausanne). 2024; 11:1356225.

PMID: 38590315 PMC: 10999571. DOI: 10.3389/fmed.2024.1356225.

Emerging role of nanotechnology in treatment of non-alcoholic fatty liver disease (NAFLD).

Moghtadaie A, Mahboobi H, Fatemizadeh S, Kamal M EXCLI J. 2023; 22:946-974.

PMID: 38023570 PMC: 10630531. DOI: 10.17179/excli2023-6420.

Unraveling the link between insulin resistance and Non-alcoholic fatty liver disease (or metabolic dysfunction-associated steatotic liver disease): A Narrative Review.

Ziamanesh F, Mohammadi M, Ebrahimpour S, Tabatabaei-Malazy O, Mosallanejad A, Larijani B J Diabetes Metab Disord. 2023; 22(2):1083-1094.

PMID: 37975107 PMC: 10638269. DOI: 10.1007/s40200-023-01293-3.

References

Saberi-Karimian M, Keshvari M, Ghayour-Mobarhan M, Salehizadeh L, Rahmani S, Behnam B . Effects of curcuminoids on inflammatory status in patients with non-alcoholic fatty liver disease: A randomized controlled trial. Complement Ther Med. 2020; 49:102322. DOI: 10.1016/j.ctim.2020.102322. View

Khodami B, Hatami B, Yari Z, Alavian S, Sadeghi A, Kord Varkaneh H . Effects of a low free sugar diet on the management of nonalcoholic fatty liver disease: a randomized clinical trial. Eur J Clin Nutr. 2022; 76(7):987-994. DOI: 10.1038/s41430-022-01081-x. View

Chiurazzi M, Cacciapuoti N, Di Lauro M, Nasti G, Ceparano M, Salomone E . The Synergic Effect of a Nutraceutical Supplementation Associated to a Mediterranean Hypocaloric Diet in a Population of Overweight/Obese Adults with NAFLD. Nutrients. 2022; 14(22). PMC: 9694188. DOI: 10.3390/nu14224750. View

Ahn S, Won Jun D, Kang B, Lim J, Lim S, Chung M . Randomized, Double-blind, Placebo-controlled Study of a Multispecies Probiotic Mixture in Nonalcoholic Fatty Liver Disease. Sci Rep. 2019; 9(1):5688. PMC: 6450966. DOI: 10.1038/s41598-019-42059-3. View

Hariri M, Gholami A, Mirhafez S, Bidkhori M, Sahebkar A . A pilot study of the effect of curcumin on epigenetic changes and DNA damage among patients with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled, clinical trial. Complement Ther Med. 2020; 51:102447. DOI: 10.1016/j.ctim.2020.102447. View

Su Q, Kim S, Adewale F, Zhou Y, Aldler C, Ni M . Single-cell RNA transcriptome landscape of hepatocytes and non-parenchymal cells in healthy and NAFLD mouse liver. iScience. 2021; 24(11):103233. PMC: 8560975. DOI: 10.1016/j.isci.2021.103233. View

Navekar R, Rafraf M, Ghaffari A, Asghari-Jafarabadi M, Khoshbaten M . Turmeric Supplementation Improves Serum Glucose Indices and Leptin Levels in Patients with Nonalcoholic Fatty Liver Diseases. J Am Coll Nutr. 2017; 36(4):261-267. DOI: 10.1080/07315724.2016.1267597. View

Zhang H, He J, Pan L, Ma Z, Han C, Chen C . Effects of Moderate and Vigorous Exercise on Nonalcoholic Fatty Liver Disease: A Randomized Clinical Trial. JAMA Intern Med. 2016; 176(8):1074-82. DOI: 10.1001/jamainternmed.2016.3202. View

Saadati S, Sadeghi A, Mansour A, Yari Z, Poustchi H, Hedayati M . Curcumin and inflammation in non-alcoholic fatty liver disease: a randomized, placebo controlled clinical trial. BMC Gastroenterol. 2019; 19(1):133. PMC: 6659284. DOI: 10.1186/s12876-019-1055-4. View

10.

Cheng S, Ge J, Zhao C, LE S, Yang Y, Ke D . Effect of aerobic exercise and diet on liver fat in pre-diabetic patients with non-alcoholic-fatty-liver-disease: A randomized controlled trial. Sci Rep. 2017; 7(1):15952. PMC: 5698376. DOI: 10.1038/s41598-017-16159-x. View

11.

Sun N, Shen C, Zhang L, Wu X, Yu Y, Yang X . Hepatic Krüppel-like factor 16 (KLF16) targets PPARα to improve steatohepatitis and insulin resistance. Gut. 2020; 70(11):2183-2195. PMC: 8515101. DOI: 10.1136/gutjnl-2020-321774. View

12.

Wang P, Ni M, Tian Y, Wang H, Qiu J, You W . Myeloid Nrf2 deficiency aggravates non-alcoholic steatohepatitis progression by regulating YAP-mediated NLRP3 inflammasome signaling. iScience. 2021; 24(5):102427. PMC: 8141901. DOI: 10.1016/j.isci.2021.102427. View

13.

Asghari S, Rezaei M, Rafraf M, Taghizadeh M, Asghari-Jafarabadi M, Ebadi M . Effects of Calorie Restricted Diet on Oxidative/Antioxidative Status Biomarkers and Serum Fibroblast Growth Factor 21 Levels in Nonalcoholic Fatty Liver Disease Patients: A Randomized, Controlled Clinical Trial. Nutrients. 2022; 14(12). PMC: 9231395. DOI: 10.3390/nu14122509. View

14.

Rahmani S, Asgary S, Askari G, Keshvari M, Hatamipour M, Feizi A . Treatment of Non-alcoholic Fatty Liver Disease with Curcumin: A Randomized Placebo-controlled Trial. Phytother Res. 2016; 30(9):1540-8. DOI: 10.1002/ptr.5659. View

15.

Blot F, Marchix J, Ejarque M, Jimenez S, Meunier A, Keime C . Gut Microbiota Remodeling and Intestinal Adaptation to Lipid Malabsorption After Enteroendocrine Cell Loss in Adult Mice. Cell Mol Gastroenterol Hepatol. 2023; 15(6):1443-1461. PMC: 10149283. DOI: 10.1016/j.jcmgh.2023.02.013. View

16.

Yamada T, Murata D, Kleiner D, Anders R, Rosenberg A, Kaplan J . Prevention and regression of megamitochondria and steatosis by blocking mitochondrial fusion in the liver. iScience. 2022; 25(4):103996. PMC: 8927900. DOI: 10.1016/j.isci.2022.103996. View

17.

Abenavoli L, Greco M, Milic N, Accattato F, Foti D, Gulletta E . Effect of Mediterranean Diet and Antioxidant Formulation in Non-Alcoholic Fatty Liver Disease: A Randomized Study. Nutrients. 2017; 9(8). PMC: 5579663. DOI: 10.3390/nu9080870. View

18.

Li L, Hou K, Yuan M, Zhang Y, Zhang Y . Change lifestyle modification plan/transtheoretical model in non-alcoholic simple fatty liver disease: a pilot randomized study. BMC Gastroenterol. 2022; 22(1):483. PMC: 9685906. DOI: 10.1186/s12876-022-02506-4. View

19.

Li Y, Chen L, Li L, Sottas C, Petrillo S, Lazaris A . Cholesterol-binding translocator protein TSPO regulates steatosis and bile acid synthesis in nonalcoholic fatty liver disease. iScience. 2021; 24(5):102457. PMC: 8113880. DOI: 10.1016/j.isci.2021.102457. View

20.

Alami F, Alizadeh M, Shateri K . The effect of a fruit-rich diet on liver biomarkers, insulin resistance, and lipid profile in patients with non-alcoholic fatty liver disease: a randomized clinical trial. Scand J Gastroenterol. 2022; 57(10):1238-1249. DOI: 10.1080/00365521.2022.2071109. View